Therapeutic Use of MicroRNAs in Lung Cancer

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Fortunato, Orazio ^a   Boeri, Mattia ^a   Verri, Carla ^a   Moro, Massimo ^a   Sozzi, Gabriella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 15A; MICRORNA 16; MICRORNA 17; MICRORNA 18; MICRORNA 19B; MICRORNA 200; MICRORNA 200C; MICRORNA 20A; MICRORNA 221; MICRORNA 222; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; MICRORNA 34; MICRORNA 34A; MICRORNA 548; MICRORNA 92; UNCLASSIFIED DRUG;

CANCER GENE THERAPY; EVALUATION STUDY; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LUNG CARCINOGENESIS; MOLECULAR PATHOLOGY; ONCOGENE; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; CARCINOGENESIS; DRUG DELIVERY SYSTEM; GENETICS; LUNG NEOPLASMS; PATHOLOGY;

ANIMALS; CARCINOGENESIS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MICRORNAS;

EID: 84920261926     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/756975     Document Type: Review

References (94)

1. R. Siegel, D. Naishadham, andA. Jemal, "Cancer statistics, 2013, " CA:ACancer Journal for Clinicians, vol. 63, no. 1, pp. 11-30, 2013.
2. R. S. Herbst, J. V. Heymach, and S. M. Lippman, "Molecular origins of cancer: lung cancer, " The New England Journal of Medicine, vol. 359, no. 13, pp. 1367-1380, 2008.
3. M. Maemondo, A. Inoue, K. Kobayashi et al., "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, " The New England Journal of Medicine, vol. 362, no. 25, pp. 2380-2388, 2010.
4. R. Rosell, E. Carcereny, R. Gervais et al., "Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, " The Lancet Oncology, vol. 13, no. 3, pp. 239-246, 2012.
5. J. F. Gainor, A. M. Varghese, S.-H. I. Ou et al., "ALK rearrangements aremutually exclusive withmutations in EGFR or KRAS: an analysis of 1, 683 patients with non-small cell lung cancer, " Clinical Cancer Research, vol. 19, no. 15, pp. 4273-4281, 2013.
6. E. L. Kwak, Y.-J. Bang, D. R. Camidge et al., "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer, " The New England Journal ofMedicine, vol. 363, no. 18, pp. 1693-1703, 2010.
7. A. T. Shaw, D.-W. Kim, K. Nakagawa et al., "Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, " The New England Journal of Medicine, vol. 368, no. 25, pp. 2385-2394, 2013.
8. D. P. Bartel, "MicroRNAs: genomics, biogenesis, mechanism, and function, " Cell, vol. 116, no. 2, pp. 281-297, 2004.
9. A. Rodriguez, S. Griffiths-Jones, J. L. Ashurst, and A. Bradley, "Identification of mammalian microRNA host genes and transcription units, " Genome Research, vol. 14, no. 10, pp. 1902-1910, 2004.
10. J. Krol, I. Loedige, and W. Filipowicz, "The widespread regulation of microRNA biogenesis, function and decay, " Nature Reviews Genetics, vol. 11, no. 9, pp. 597-610, 2010.
11. G. A. Calin and C. M. Croce, "MicroRNA signatures in human cancers, " Nature Reviews Cancer, vol. 6, no. 11, pp. 857-866, 2006.
12. J. Hayes, P. P. Peruzzi, and S. Lawler, "MicroRNAs in cancer: biomarkers, functions and therapy, " Trends in Molecular Medicine, vol. 20, no. 8, pp. 460-469, 2014.
13. L. G. Di, M. Garofalo, and C. M. Croce, "MicroRNAs in cancer, " Annual Review of Pathology, vol. 9, pp. 287-314, 2014.
14. W.-C. Zhang, J. Liu, X. Xu, and G. Wang, "The role of microRNAs in lung cancer progression, " Medical Oncology, vol. 30, no. 3, pp. 1-9, 2013.
15. G. Sozzi, U. Pastorino, and C. M. Croce, "MicroRNAs and lung cancer: from markers to targets, " Cell Cycle, vol. 10, no. 13, pp. 2045-2046, 2011.
16. N. Yanaihara, N. Caplen, E. Bowman et al., "Unique microRNA molecular profiles in lung cancer diagnosis and prognosis, " Cancer Cell, vol. 9, no. 3, pp. 189-198, 2006.
17. M. Boeri, C. Verri, D. Conte et al., "MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 9, pp. 3713-3718, 2011.
18. A. Bischoff, B. Huck, B. Keller et al., "miR-149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion, " Cancer Research, 2014.
19. L. Du, J. J. Schageman, M. C. Subauste et al., "miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1, " Molecular Cancer Research, vol. 7, no. 8, pp. 1234-1243, 2009.
20. Y. Peng, Y. Dai, C. Hitchcock et al., "Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer, " Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 37, pp. 15043-15048, 2013.
21. X. L. Xu, Y. H. Jiang, J. G. Feng, D. Su, P. C. Chen, and W. M. Mao, "MicroRNA-17, microRNA-18a, and microRNA-19a are prognostic indicators in esophageal squamous cell carcinoma, " TheAnnals of Thoracic Surgery, vol. 97, no. 3, pp. 1037-1045, 2014.
22. J. Hu, Y. Cheng, Y. Li et al., "microRNA-128 plays a critical role in human non-small cell lung cancer tumourigenesis , angiogenesis and lymphangiogenesis by directly targeting vascular endothelial growth factor-C, " European Journal of Cancer, vol. 50, no. 13, pp. 2336-2350, 2014.
23. P. Trang, J. B. Weidhaas, and F. J. Slack, "MicroRNAs as potential cancer therapeutics, " Oncogene, vol. 27, supplement 2, pp. S52-S57, 2008.
24. M. Raponi, L. Dossey, T. Jatkoe et al., "MicroRNA classifiers for predicting prognosis of squamous cell lung cancer, " Cancer Research, vol. 69, no. 14, pp. 5776-5783, 2009.
25. Y. Lu, R. Govindan, L. Wang et al., "MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer, " Carcinogenesis, vol. 33, no. 5, pp. 1046-1054, 2012.
26. Y. Xia, Y. Zhu, X. Zhou, and Y. Chen, "Low expression of let-7 predicts poor prognosis in patients with multiple cancers: a meta-analysis, " Tumor Biology, vol. 35, no. 6, pp. 5143-5148, 2014.
27. M. T. Landi, Y. Zhao, M. Rotunno et al., "MicroRNA expression differentiates histology and predicts survival of lung cancer, " Clinical Cancer Research, vol. 16, no. 2, pp. 430-441, 2010.
28. S. M. Johnson, H. Grosshans, J. Shingara et al., "RAS is regulated by the let-7 microRNA family, " Cell, vol. 120, no. 5, pp. 635-647, 2005.
29. S. L. Yong andA. Dutta, "The tumor suppressormicroRNAlet-7 represses the HMGA2 oncogene, " Genes and Development, vol. 21, no. 9, pp. 1025-1030, 2007.
30. V. B. Sampson, N. H. Rong, J. Han et al., "MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells, " Cancer Research, vol. 67, no. 20, pp. 9762-9770, 2007.
31. S. Tokumaru, M. Suzuki, H. Yamada, M. Nagino, and T. Takahashi, "let-7 regulates Dicer expression and constitutes a negative feedback loop, " Carcinogenesis, vol. 29, no. 11, pp. 2073-2077, 2008.
32. C. D. Johnson, A. Esquela-Kerscher, G. Stefani et al., "The let-7 microRNA represses cell proliferation pathways in human cells, " Cancer Research, vol. 67, no. 16, pp. 7713-7722, 2007.
33. A. Esquela-Kerscher, P. Trang, J. F. Wiggins et al., "The let microRNA reduces tumor growth in mouse models of lung cancer, " Cell Cycle, vol. 7, no. 6, pp. 759-764, 2008.
34. J. B. Weidhaas, I. Babar, S. M. Nallur et al., "MicroRNAs as potential agents to alter resistance to cytotoxic anticancer therapy, " Cancer Research, vol. 67, no. 23, pp. 11111-11116, 2007.
35. E. Gallardo, A. Navarro, N. Vinolas et al., "miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer, " Carcinogenesis, vol. 30, no. 11, pp. 1903-1909, 2009.
36. C. Welch, Y. Chen, and R. L. Stallings, "MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells, " Oncogene, vol. 26, no. 34, pp. 5017-5022, 2007.
37. C. S. Chim, K. Y. Wong, Y. Qi et al., "Epigenetic inactivation of the miR-34a in hematological malignancies, " Carcinogenesis, vol. 31, no. 4, pp. 745-750, 2010.
38. D. C. Corney, C.-I. Hwang, A. Matoso et al., "Frequent downregulation ofmiR-34 family in human ovarian cancers, " Clinical Cancer Research, vol. 16, no. 4, pp. 1119-1128, 2010.
39. A. G. Bader, "MiR-34: a microRNA replacement therapy is headed to the clinic, " Frontiers in Genetics, vol. 3, article 120, 2012.
40. L. He, X. He, L. P. Lim et al., "A microRNA component of the p53 tumour suppressor network, " Nature, vol. 447, no. 7148, pp. 1130-1134, 2007.
41. G. T. Bommer, I. Gerin, Y. Feng et al., "p53-mediated activation of mirna34 candidate tumor-suppressor genes, " Current Biology, vol. 17, no. 15, pp. 1298-1307, 2007.
42. M. Garofalo, Y.-J. Jeon, G. J. Nuovo et al., "MiR-34a/cdependent PDGFR-α/β downregulation inhibits tumorigenesis and enhances TRAIL-induced apoptosis in lung cancer, " PLoS ONE, vol. 8, no. 6, Article ID e67581, 2013.
43. A. L. Kasinski and F. J. Slack, "MiRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma, " Cancer Research, vol. 72, no. 21, pp. 5576-5587, 2012.
44. S. Volinia, G. A. Calin, C.-G. Liu et al., "A microRNA expression signature of human solid tumors defines cancer gene targets, " Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 7, pp. 2257-2261, 2006.
45. H. Stenvold, T. Donnem, S. Andersen et al., "High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome, "BMC Clinical Pathology, vol. 14, no. 1, p. 9, 2014.
46. W. Gao, H. Shen, L. Liu, J. Xu, J. Xu, and Y. Shu, "MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis, " Journal of Cancer Research and Clinical Oncology, vol. 137, no. 4, pp. 557-566, 2011.
47. A. Capodanno, L. Boldrini, A. Proietti et al., "Let-7g and miR-21 expression in non-small cell lung cancer: correlation with clinicopathological and molecular features, " International Journal of Oncology, vol. 43, no. 3, pp. 765-774, 2013.
48. M. Yang, H. Shen, C. Qiu et al., "High expression ofmiR-21 and miR-155 predicts recurrence and unfavourable survival in nonsmall cell lung cancer, " European Journal of Cancer, vol. 49, no. 3, pp. 604-615, 2013.
49. Z.-X. Wang, H.-B. Bian, J.-R. Wang, Z.-X. Cheng, K.-M. Wang, andW. De, "Prognostic significance of serummiRNA-21 expression in human non-small cell lung cancer, " Journal of Surgical Oncology, vol. 104, no. 7, pp. 847-851, 2011.
50. I. Bhatti, A. Lee, V. James et al., "Knockdown of microRNA inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma, " Journal of Gastrointestinal Surgery, vol. 15, no. 1, pp. 199-208, 2011.
51. I. A. Asangani, S. A. K. Rasheed, D. A. Nikolova et al., "Micro-RNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer, " Oncogene, vol. 27, no. 15, pp. 2128-2136, 2008.
52. J.-G. Zhang, J.-J. Wang, F. Zhao, Q. Liu, K. Jiang, and G.-H. Yang, "MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC), " Clinica Chimica Acta, vol. 411, no. 11-12, pp. 846-852, 2010.
53. S. Zhu, H. Wu, F. Wu, D. Nie, S. Sheng, and Y.-Y. Mo, "MicroRNA-21 targets tumor suppressor genes in invasion and metastasis, " Cell Research, vol. 18, no. 3, pp. 350-359, 2008.
54. B. Li, S. Ren, X. Li et al., "MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer, " Lung Cancer, vol. 83, no. 2, pp. 146-153, 2014.
55. M. E. Hatley, D. M. Patrick, M. R. Garcia et al., "Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21, " Cancer Cell, vol. 18, no. 3, pp. 282-293, 2010.
56. Y. Hayashita, H. Osada, Y. Tatematsu et al., "A polycistronic MicroRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation, " Cancer Research, vol. 65, no. 21, pp. 9628-9632, 2005.
57. H. Y. Jin, H. Oda, M. Lai et al., "MicroRNA-17∼92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways, " EMBO Journal, vol. 32, no. 17, pp. 2377-2391, 2013.
58. Q. Wu, Z. Yang, F. Wang et al., "MiR-19b/20a/92a regulates the self-renewal and proliferation of gastric cancer stem cells, " Journal of Cell Science, vol. 126, part 18, pp. 4220-4229, 2013.
59. B. L. Murphy, S. Obad, L. Bihannic et al., "Silencing of the miR-17∼92 cluster family inhibits medulloblastoma progression, " Cancer Research, vol. 73, no. 23, pp. 7068-7078, 2013.
60. K. A. ODonnell, E. A. Wentzel, K. I. Zeller, C. V. Dang, and J. T. Mendell, "c-Myc-regulated microRNAs modulate E2F1 expression, " Nature, vol. 435, no. 7043, pp. 839-843, 2005.
61. C. Xiao, L. Srinivasan, D. P. Calado et al., "Lymphoproliferative disease and autoimmunity in mice with increased miR-17-92 expression in lymphocytes, " Nature Immunology, vol. 9, no. 4, pp. 405-414, 2008.
62. A. Ventura, A. G. Young, M. M. Winslow et al., "Targeted deletion reveals essential and overlapping functions of themiR through 92 family of miRNA cluster, " Cell, vol. 132, no. 5, pp. 875-886, 2008.
63. H. Matsubara, T. Takeuchi, E. Nishikawa et al., "Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92, " Oncogene, vol. 26, no. 41, pp. 6099-6105, 2007.
64. F. Chen, S. K. Hou, H. J. Fan, andY. F. Liu, "MiR-15a-16 represses Cripto and inhibits NSCLC cell progression, " Molecular and Cellular Biochemistry, vol. 39, no. 1-2, pp. 11-19, 2014.
65. Y. Ke, W. Zhao, J. Xiong, and R. Cao, "Downregulation ofmiR promotes growth and motility by targeting HDGF in nonsmall cell lung cancer cells, " FEBS Letters, vol. 587, no. 18, pp. 3153-3157, 2013.
66. N. Bandi, S. Zbinden, M. Gugger et al., "miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer, " Cancer Research, vol. 69, no. 13, pp. 5553-5559, 2009.
67. N. Bandi and E. Vassella, "MiR-34a and miR-15a/16 are coregulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner, " Molecular Cancer, vol. 10, article 55, 2011.
68. P. Ceppi, G. Mudduluru, R. Kumarswamy et al., "Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer, " Molecular Cancer Research, vol. 8, no. 9, pp. 1207-1216, 2010.
69. Y. Yang, Y. H. Ahn, Y. Chen et al., "ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism, " Journal of Clinical Investigation, vol. 124, no. 6, pp. 2696-2708, 2014.
70. Y. Takeyama, M. Sato, M. Horio et al., "Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells, " Cancer Letters, vol. 296, no. 2, pp. 216-224, 2010.
71. D. L. Gibbons, W. Lin, C. J. Creighton et al., "Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression, " Genes andDevelopment, vol. 23, no. 18, pp. 2140-2151, 2009.
72. M. Pacurari, J. B. Addison, N. Bondalapati et al., "The micro-RNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells, " International Journal of Oncology, vol. 43, no. 2, pp. 548-560, 2013.
73. R. Tejero, A. Navarro, M. Campayo et al., "miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma, " PLoS ONE, vol. 9, no. 7, Article ID e101899, 2014.
74. M. Fabbri, R. Garzon, A. Cimmino et al., "MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 40, pp. 15805-15810, 2007.
75. M. Garofalo, C. Quintavalle, G. di Leva et al., "MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer, " Oncogene, vol. 27, no. 27, pp. 3845-3855, 2008.
76. M. Garofalo, G. Di Leva, G. Romano et al., "miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation, " Cancer Cell, vol. 16, no. 6, pp. 498-509, 2009.
77. M. Garofalo, G. Romano, G. Di Leva et al., "EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers, " Nature Medicine, vol. 18, no. 1, pp. 74-82, 2012.
78. B. Hu, X. Ying, J. Wang et al., "Identification of a tumor-suppressive human-specific microRNA within the FHIT tumorsuppressor gene, " Cancer Research, vol. 74, no. 8, pp. 2283-2294, 2014.
79. P. Trang, P. P. Medina, J. F. Wiggins et al., "Regression of murine lung tumors by the let-7 microRNA, " Oncogene, vol. 29, no. 11, pp. 1580-1587, 2010.
80. J. F. Wiggins, L. Ruffino, K. Kelnar et al., "Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34, " Cancer Research, vol. 70, no. 14, pp. 5923-5930, 2010.
81. P. Trang, J. F. Wiggins, C. L. Daige et al., "Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice, "MolecularTherapy, vol. 19, no. 6, pp. 1116-1122, 2011.
82. C. N. Landen Jr., A. Chavez-Reyes, C. Bucana et al., "Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery, " Cancer Research, vol. 65, no. 15, pp. 6910-6918, 2005.
83. G.-Y. Chiou, J.-Y. Cherng, H.-S. Hsu et al., "Cationic polyurethanes-short branch PEI-mediated delivery of Mir145 inhibited epithelial-mesenchymal transdifferentiation and cancer stem-like properties and in lung adenocarcinoma, " Journal of Controlled Release, vol. 159, no. 2, pp. 240-250, 2012.
84. Y. Shi, C. Liu, X. Liu, D. G. Tang, and J. Wang, "The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells, " PLoS ONE, vol. 9, no. 3, Article ID e90022, 2014.
85. Y. Wu, M. Crawford, Y. Mao et al., "Therapeutic delivery of MicroRNA-29b by cationic lipoplexes for lung cancer, " Molecular Therapy-Nucleic Acids, vol. 2, article e84, 2013.
86. M. A. Cortez, D. Valdecanas, X. Zhang et al., "Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer, " MolecularTherapy, vol. 22, no. 8, pp. 1494-1503, 2014.
87. A. Esquela-Kerscher and F. J. Slack, "Oncomirs: microRNAs with a role in cancer, " Nature Reviews Cancer, vol. 6, no. 4, pp. 259-269, 2006.
88. E. van Rooij and E. N. Olson, "MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets, " Journal of Clinical Investigation, vol. 117, no. 9, pp. 2369-2376, 2007.
89. D. H. Kimand J. J. Rossi, "Strategies for silencing human disease using RNA interference, " Nature Reviews Genetics, vol. 8, no. 3, pp. 173-184, 2007.
90. C. V. Pecot, G. A. Calin, R. L. Coleman, G. Lopez-Berestein, and A. K. Sood, "RNA interference in the clinic: challenges and future directions, " Nature Reviews Cancer, vol. 11, no. 1, pp. 59-67, 2011.
91. J. A. Broderick and P. D. Zamore, "MicroRNA therapeutics, " GeneTherapy, vol. 18, no. 12, pp. 1104-1110, 2011.
92. S. I. Pai, Y. Y. Lin, B. Macaes, A. Meneshian, C. F. Hung, and T. C. Wu, "Prospects of RNA interference therapy for cancer, " GeneTherapy, vol. 13, no. 6, pp. 464-477, 2006.
93. L. Jiang, Q. Huang, S. Zhang et al., "Hsa-miR-125a-3p and hsamiR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells, " BMC Cancer, vol. 10, article 318, 2010.
94. J. Krutzfeldt, N. Rajewsky, R. Braich et al., "Silencing of microRNAs in vivo with "antagomirs", " Nature, vol. 438, no. 7068, pp. 685-689, 2005.